PubMed:25118236 / 0-920 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed/sourceid/25118236","sourcedb":"PubMed","sourceid":"25118236","source_url":"https://www.ncbi.nlm.nih.gov/pubmed/25118236","text":"Whole-animal chemical screen identifies colistin as a new immunomodulator that targets conserved pathways.\nUNLABELLED: The purpose of this study was to take advantage of the nematode Caenorhabditis elegans to perform a whole-animal chemical screen to identify potential immune activators that may confer protection against bacterial infections. We identified 45 marketed drugs, out of 1,120 studied compounds, that are capable of activating a conserved p38/PMK-1 mitogen-activated protein kinase pathway required for innate immunity. One of these drugs, the last-resort antibiotic colistin, protected against infections by the Gram-negative pathogens Yersinia pestis and Pseudomonas aeruginosa but not by the Gram-positive pathogens Enterococcus faecalis and Staphylococcus aureus. Protection was independent of the antibacterial activity of colistin, since the drug was administered prophylactically prior to the infect","tracks":[]}